Frequently Asked Questions
The market is segmented based on Global Human Insulin Drugs and Delivery Devices Market Segmentation, By Product (Human Insulin (HI) Drugs, Human Insulin (HI) Delivery Devices), Drug (Insulin Analogs and Biosimilar, Long-Acting Biosimilar, Rapid-Acting Biosimilar, Premixed Biosimilar, Human Insulin Biologics, Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics), Delivery Device (Syringes, Pens, Disposable Pens, Reusable Pens, Pen Needles, Standard Pen Needles, Safety Pen Needles), Application (Type I Diabetes, Type II Diabetes), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.
.
The Global Human Insulin Drugs And Delivery Devices Market size was valued at USD 50.21 USD Billion in 2023.
The Global Human Insulin Drugs And Delivery Devices Market is projected to grow at a CAGR of 8.25% during the forecast period of 2024 to 2031.
The major players operating in the market include Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Novartis AG, Bayer AG, Lilly, Merck & Co. , AstraZeneca, Johnson & Johnson Private Limited, Biocon, Boehringer Ingelheim International GmbH., Medtronic, Ypsomed AG, Julphar, Albireo Pharma , CeQur Simplicity, BD, B. Braun SE, Novo Nordisk A/S, WOCKHARDT .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
